Dermal toxicity: alternative methods for risk assessment. by Goldberg, A M & Maibach, H I
Dermal Toxicity: Alternative Methods
for RiskAssessment
Alan M. Goldberg1 and Howard 1. Maibach2
1Johns Hopkins University, School of Hygiene and Public Health,
Baltimore, Maryland; 2University of California Medical School,
San Francisco, California
Conceptually, irritant contact dermatitis (irritation) and allergic contact dermatitis (ACD) in man
should provide the ideal platforms to launch in vitrotoxicology into the pantheon of in vitrotesting
assays. In theory, irritant dermatitis has been considered by most a simple area of cutaneous
biology, whereas ACD is a complex area of biology. However, both result in responses that are
reasonably stereotypical and well characterized. The biology of the underlying mechanisms is
becoming characterized and will thus allow development of mechanistically based in vitro assays
that will be scientifically validated and thus acceptable to regulatory agencies. Environ Health
Perspect 106(Suppl 2):493-496 (1998). http.//eehpnetl.niehs.nih.gov/docs/1998/Suppl-2/493-
496goldberg/abstract.html
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Irritant Dermatitis Syndrome:
Contemporary (Tentative)
Definition
Dermatopathologists and toxicologists
generally consider cutaneous irritation a
homogeneous and monomorphous bio-
logic event, having been lulled by its
mundane morphology. However, current
knowledge suggests the contrary-a rela-
tively homogeneous appearance but a com-
plex, variegated sequence of mechanisms.
Our current clinical and mechanistic classi-
fication (Table 1) undoubtedly represents a
vast undersimplification, as we are only
beginning to understand this common and
heterogeneous syndrome.
Irritant Dermatitis Syndrome:
Localized or Systemic?
Conventional dogma suggests that irritant
dermatitis is a localized (site of contact)
phenomenon; surely the reasoning appears
impeccable. Yet, current knowledge sug-
gests that, although the point of contact
phenomena must be primal, other sys-
temic factors may be decisive. Some possi-
ble systemic factors influencing irritant
dermatitis are a) age, b) race, c) preexist-
ing and/or previous skin diseases, and
d) atopic dermatitis.
Irritation in Vtro
Methods to evaluate potential irritation
have been well described in In Vitro Skin
Toxicology (1).
For irritancy testing, physical-chemical
measurements, quantitative structure-
activity relationship (QSAR), and historical
data can provide significant data. In vitro
methods that measure cytotoxic inter-
leukins (ILs)la, arachidonic acid, and the
prostaglandins (1,2) should provide ade-
quate information on acute mild irritants
through and including corrosivity. Addi-
tionally, reconstituted tissue equivalents
(RTE) and skin explants may be useful in
other situations.
All these systems are in development or
in use in research laboratories. They have
not gone through adequate optimization yet
to be ready for validation, but one can
expect that this will begin to happen in the
near future. Table 2 is not meant to be
indusive, but to identify current, best-guess
approaches to specific end points. There is a
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substantial need to a) more clearly define
relationships between interleukins (both
time relationship and biologic interactions);
b) understand the biology ofadhesion mol-
ecules; c) improve and define the conditions
of the biologic systems; and d) establish
relationships between these biochemical sys-
tems, molecules, and exogenous chemicals.
In evaluating acute toxicants (including
dermal), it has been suggested that once data
from in vitro testing are evaluated, including
what is known about the chemicals and
evaluation of these chemicals [e.g., QSAR
(3,4), literature, physical-chemical mea-
sures], it may then be appropriate to estab-
lish safety of these materials directly in the
human (Figure 1).
Corrosivity, a physical destruction ofthe
skin, is the extreme case of irritancy. It is
likely that in the near future we will be able
to predict corrosive ability using QSAR,
physical and chemical assays, and historical
information to fullyassess the hazard (3-6).
It is inappropriate for us to assess the degree
of severe corrosives using either whole
animal orhuman clinical studies.
Phototoxicity
Dermal phototoxicity results from
photo-activation of chemicals that cause
either a photoirritant or a photoallergic
response. A method to examine phototoxi-
city has recently been described (7,8). The
developers of this assay suggest that it is
validated, but it has not yet been submitted
for fully independent, anonymous peer
Table 1. Clinical classification of irritation.
Irritation Onset
Objective
Acute (primary Acute, often
irritantdermatitis) single exposure
Corrosion(severe Acute, often
form ofabove) single exposure
Irritant reaction Acute, often
multiple exposure
Delayed acute Delayed 12 to 24
irritant dermatitis hr or longer
Cumulative irritant Slowlydeveloping
contactdermatitis (weeks toyears)
Traumatic irritant Slowlydeveloping after
dermatitis preceding trauma
Pustular and acneiform Pustularform may
dermatitis develop in days
Nonerythematous Acute to slowly
irritation developing
Friction Slowlydeveloping
Subjective
Sensory irritation Minutes
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Table2. In vitrosystems: an approach to dermal toxicity.
End point
Biologic system Irritant Corrosion ACD
Cell culture MTT, arachidonic acid Arachidonic acid [L-8
Prostaglandins, IL-ax Prostaglandins B7
RTE and skin explants All ofthe above plus Histochemistry Histochemistry
histochemistry and Arachidonic acid B7
bioengineering measures e.g., Prostaglandins IL-8
transepithelial water loss
Dendritic cells and models NA NA T-lymphocyte
(bloodmonocytes) activation
Abbreviations: NA, notapplicable; MTT, 3[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide.
Figure 1. System for using in vitroassays as part of a tiered testing structure. Thediagram illustrates a sequential
process for making the safety assessment of a hypothetical chemical or product. It can be seen that in vitro meth-
ods (as well as traditional animal tests) supply only a portion ofthe information needed to make thesafetyassess-
ment and thatthis information is integrated with other data so that a weight-of-evidence decision is finally made.
From Curren etal. (36).
review. A guideline document is being
prepared for submission to the Organ-
isation for Economic Co-operation and
Development (OECD).
AllergicContactDermatitis
Allergic contact dermatitis (ACD) is a
complex set of biologic reactions that is
not yet fully understood. However, sig-
nificant advances in defining an approach
to predict the phenomenon is rapidly
developing. ACD is the result of cuta-
neous T-lymphocyte-mediated reaction
to exogenous chemicals.
The biology of ACD has been well
described by Elmets (9) and relevant
sections are quoted here for easy reference.
Once complete antigens have been
formed, they are "taken up" by Langer-
hans cells within the epidermis and
other antigen presenting cells, such as
macrophages and dendritic cells,
within the dermis (10-12). Epidermal
Langerhans cells are a specialized type
of antigen-presenting cell (13). They
comprise 2-4% ofthe entire epidermal
cell population. These cells are derived
from the bone marrow, and migrate to
the suprabasilar layer of the epidermis
where they reside for long periods of
time. In that location they form a
reticulo-endothelial network that
traps: a) exogenous xenobiotics that
may have deleterious effects on the
skin, b) pathogenic microorganisms that
maycause alocal or systemic disease and
c) neoantigens on cells that without
eradication woulddevelop intodinically
apparent tumors (10). The major func-
tion ofepidermal Langerhans cells and
other antigen-presenting cells is to acti-
vate subpopulations ofantigen reactive
T-lymphocytes (11). As their part of
their role as antigen-presenting cells,
Langerhans cells "take-up" antigen and
degrade it within lysosomal granules or
in theendoplasmic reticulum and then
reexpress thedegraded molecule on the
cell surface complexed with class I
or class II major histocompatibility
determinants. While this is occurring,
Langerhans cells migrate to regional
lymph nodes, a site where theyactually
present the antigen to T-lymphocytes
(14). Interestingly, while they migrate
Langerhans cells undergo a series of
differentiation steps that prepare them
to more efficiently present the antigen
to T cells (15,16). This includes an
increase in the expression of class II
major histocompatibility determinants
(17) and of the adhesion molecules
ICAM-1 [CD54] (18,19), B7-1
[CD80] (20,21), and B7-2 [CD86]
(20). The costimulatory molecules
ICAM-1, B7-1 and B7-2 are impor-
tant adhesion molecules, which are
expressed on antigen-presenting cells
and are required for optimal activation
of T cells. During this differentiation
process, Langerhans cells also lose their
ability to process antigens (15,22) and
their capacity to express E-cadherin, an
adhesion molecule that allows Langer-
hans cells to attach to keratinocytes
(23). The cytokines GM-CSF (20,24)
and, to a lesser extent, IL-1 (24) are
intimately involved in stimulating
Langerhans cell maturation.
...Once Langerhans cells havepresented
the hapten carrier complex to T cells,
the T cells proliferate and differentiate
and return to the site ofhapten applica-
tion in the skin where they are respon-
sible for creating an inflammatory
response that is recognized clinically as
allergic contact dermatitis. Recent stud-
ies have shown that not all T cells can
recirculate back to the site ofantigen
application. Only T cells that express
specific adhesion molecules do so. Of
particular importance in this regard are
thea4Bl anda4B7 integrins (25).
...Keratinocytes, the predominant
epidermal cell type, contribute to the
immunopathogenesis ofallergic contact
dermatitis in two ways - first, through
the induced expression of adhesion
molecules that facilitate interactions
with T cells and second by thesynthesis
and secretion of a variety of soluble
polypeptidecytokines.
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Interleukin-8 (IL-8) is an 8-kDa
heparin-binding basic polypeptide that is
chemotactic for T cells (26). There is evi-
dence that it acts in that capacity to bring
in T cells into cutaneous sites in urushiol
allergic contact dermatitis (27). IL-8
mRNA can be induced in cultured ker-
atinocytes in response to IL-1oa (26).
The complexity ofthe biology, presented
alone, provides many opportunities to
develop a battery of in vitro tests based on
mechanistic understanding (28-33).
The potential systems and end points
are summarized inTable 2.
If one uses the schematic in Figure 1
then QSAR, historical data, and literature
may provide adequate data to classify a
compound or will identify which specific in
vitro tests will be appropriate. The next
sequential step will be to use cell culture and
RTE and measure appropriate cytokines,
adhesion molecules, and/or histochemistry.
Needs and Future Direction
Many methods have been evaluated by
different laboratories. There is a clear need
for additional studies to more completely
define and identify the underlying biology
of the cytokines, adhesion molecules, and
other inflammatory molecules. This
knowledge will provide the rationale for
specific batteries ofin vitro tests to provide
measures of irritancy, corrosivity, and
allergic potential.
What remains to be done is not only
validating the assays for man. This is a
needed step, but only after appropriate
methods are fully developed to generally
accepted standards ofscientific rigor using
in principle the criteria described by the
Interagency Coordinating Committee for
the Validation of Alternative Methods
(34) and the OECD (35) for validation
and regulatory acceptance. Then an under-
standing of how to use the information
appropriately for risk assessment will be
the next challenge.
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